Skip to main content Back to Top
Advertisement

11/2/2024

Amoxicillin and Clavulanate Oral Presentations

Products Affected - Description

    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 66685-1011-00 - discontinued
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 66685-1012-00 - discontinued
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 66685-1012-01
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00093-2277-73
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00093-8675-75
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00093-8675-74
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00093-8675-78
    • Amoxicillin and Clavulanate oral tablet, Teva, 200 mg/28.5 mg, 20 count, NDC 00093-2270-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 400 mg/57 mg, 20 count, NDC 00093-2272-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 500 mg/125 mg, 20 count, NDC 00093-2274-34
    • Amoxicillin and Clavulanate oral tablet, Teva, 875 mg/125 mg, 20 count, NDC 00093-2275-34
    • Amoxicillin and Clavulanate oral powder for suspension, Wockhardt USA, 250 mg/5 mL - 62.5 mg/5 mL, 100 mL bottle, 1 count, NDC 60432-0065-00 - discontinued
    • Amoxicillin and Clavulanate oral powder for suspension, Wockhardt USA, 250 mg/5 mL - 62.5 mg/5 mL, 150 mL bottle, 1 count, NDC 60432-0065-47 - discontinued
    • Amoxicillin and Clavulanate oral powder for suspension, Wockhardt USA, 250 mg/5 mL - 62.5 mg/5 mL, 75 mL bottle, 1 count, NDC 60432-0065-75 - discontinued

Reason for the Shortage

    • Aurobindo refuses to provide availability information.
    • Hikma has amoxicillin and clavulanate oral presentations available.
    • Micro Labs was not available to provide information.
    • Sandoz did not provide a reason for the shortage of the oral powder for suspension 400 mg/5 mL in 75 mL bottles. The 50 mL bottles have been discontinued.
    • Teva did not provide a reason for the shortage.
    • US Antibiotics has amoxicillin and clavulanate oral suspension available.
    • Wockhardt is discontinuing amoxicillin and clavulanate oral presentations in October 2024. Remaining inventories in wholesaler channels will be distributed until depleted.

Available Products

    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9981-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9981-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9981-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00143-9982-01
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 50 mL bottle, 1 count, NDC 00143-9982-50
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 400 mg/5 mL - 57 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9982-75
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00143-9853-16
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00143-9853-24
    • Amoxicillin and Clavulanate oral powder for suspension, Hikma, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00143-9853-75
    • Amoxicillin and Clavulanate oral tablet, Hikma, 875 mg/125 mg, 20 count, NDC 00143-9249-20
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 28 count, NDC 00781-1943-82
    • Amoxicillin and Clavulanate oral extended release tablet, Sandoz, 1000 mg / 62.5 mg, 40 count, NDC 00781-1943-39
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6102-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 200 mg/5 mL - 28.5 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6102-57
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00781-6104-46
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 00781-6139-54
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 00781-6139-48
    • Amoxicillin and Clavulanate oral powder for suspension, Sandoz, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 00781-6139-57
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 250 mg / 125 mg, 30 count, NDC 00781-1874-31
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 20 count, NDC 00781-1831-20
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 500 mg / 125 mg, 100 count, NDC 00781-1831-01
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 20 count, NDC 00781-1852-20
    • Amoxicillin and Clavulanate oral tablet, Sandoz, 875 mg / 125 mg, 100 count, NDC 00781-1852-01
    • Amoxicillin and Clavulanate oral powder for suspension, Teva, 400 mg/5 mL - 57 mg/5 mL, 100 mL bottle, 1 count, NDC 00093-2279-73
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 125 mL bottle, 1 count, NDC 81964-0206-69
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 200 mL bottle, 1 count, NDC 81964-0203-54
    • Amoxicillin and Clavulanate oral powder for suspension, US Antibiotics, 600 mg/5 mL - 42.9 mg/5 mL, 75 mL bottle, 1 count, NDC 81964-0203-51

Estimated Resupply Dates

    • Sandoz has amoxicillin and clavulanate 400 mg/5 mL - 57 mg/5 mL in 75 mL oral powder for suspension on back order and the company cannot estimate a release date.
    • Teva has amoxicillin and clavulanate 200 mg/5 mL - 28.5 mg/5 mL in 100 mL, 600 mg/5mL - 42.9 mg/5 mL in 75 mL and 200 mL, 600 mg/5 mL - 42.9 mg/5 mL in 125 mL bottles, and 500 mg/125 mg tablets on intermittent back order and the company is releasing supplies as they become available. The 200 mg/28.5 mg tablets and 400 mg/47 mg tablets in 20 count bottles are on back order and the company cannot estimate a release date. The 875 mg/125 mg tablets in 20 count are on back order and the company estimates a resupply in early-November 2024.

Updated

Updated November 2, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created November 18, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT